$CTMX
CytomX Therapeutics Inc

2020 Q3 Form 10-Q Financial Statement

#000156459020037722 Filed on August 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2019 Q2
Revenue $17.79M $16.61M $9.013M
YoY Change 66.06% 84.27% -57.76%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.630M $8.680M $9.410M
YoY Change 2.01% -7.76% 4.09%
% of Gross Profit
Research & Development $24.05M $24.07M $30.84M
YoY Change -14.01% -21.95% 20.67%
% of Gross Profit
Depreciation & Amortization $600.0K $700.0K $700.0K
YoY Change -14.29% 0.0% 40.0%
% of Gross Profit
Operating Expenses $32.68M $32.75M $40.25M
YoY Change -10.29% -18.64% 16.33%
Operating Profit -$14.90M -$16.14M -$31.23M
YoY Change -42.08% -48.33% 135.6%
Interest Expense $200.0K $450.0K $2.360M
YoY Change -90.0% -80.93% 53.25%
% of Operating Profit
Other Income/Expense, Net -$15.00K $5.000K -$90.00K
YoY Change -168.18% -105.56% -250.0%
Pretax Income -$14.71M -$15.68M -$28.96M
YoY Change -37.93% -45.86% 148.46%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$14.71M -$15.68M -$28.96M
YoY Change -37.93% -45.86% 115.36%
Net Earnings / Revenue -82.7% -94.41% -321.31%
Basic Earnings Per Share
Diluted Earnings Per Share -$318.4K -$340.4K -$638.7K
COMMON SHARES
Basic Shares Outstanding 46.19M 45.92M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $321.1M $346.4M $349.1M
YoY Change -1.42% -0.79% 4.19%
Cash & Equivalents $176.8M $291.4M $149.4M
Short-Term Investments $144.3M $55.00M $199.8M
Other Short-Term Assets $5.600M $6.900M $7.500M
YoY Change -38.46% -8.0% 17.19%
Inventory
Prepaid Expenses
Receivables $500.0K $200.0K $10.00M
Other Receivables $13.10M $13.10M $0.00
Total Short-Term Assets $340.3M $366.6M $366.7M
YoY Change 1.65% -0.02% -0.01%
LONG-TERM ASSETS
Property, Plant & Equipment $30.40M $31.40M $7.238M
YoY Change 327.75% 333.82% 31.6%
Goodwill $949.0K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.300M $2.300M $1.375M
YoY Change 67.27% 67.27% -40.22%
Total Long-Term Assets $34.90M $35.90M $38.61M
YoY Change -7.59% -7.01% 278.5%
TOTAL ASSETS
Total Short-Term Assets $340.3M $366.6M $366.7M
Total Long-Term Assets $34.90M $35.90M $38.61M
Total Assets $375.2M $402.5M $405.3M
YoY Change 0.71% -0.69% 7.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.600M $4.900M $4.520M
YoY Change -20.88% 8.41% 7.62%
Accrued Expenses $23.95M $21.15M $22.47M
YoY Change 16.83% -5.88% -9.4%
Deferred Revenue $51.68M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $102.0M $98.80M $78.67M
YoY Change 33.99% 25.58% -5.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $225.1M $244.9M $963.0K
YoY Change 23274.87% 25330.94% -99.62%
Total Long-Term Liabilities $225.1M $244.9M $963.0K
YoY Change 23274.87% 25330.94% -99.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $102.0M $98.80M $78.67M
Total Long-Term Liabilities $225.1M $244.9M $963.0K
Total Liabilities $327.1M $343.7M $303.8M
YoY Change 12.62% 13.14% -9.53%
SHAREHOLDERS EQUITY
Retained Earnings -$358.1M
YoY Change
Common Stock $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $48.06M $58.83M $101.5M
YoY Change
Total Liabilities & Shareholders Equity $375.2M $402.5M $405.3M
YoY Change 0.71% -0.69% 7.53%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$14.71M -$15.68M -$28.96M
YoY Change -37.93% -45.86% 115.36%
Depreciation, Depletion And Amortization $600.0K $700.0K $700.0K
YoY Change -14.29% 0.0% 40.0%
Cash From Operating Activities -$24.70M $97.10M -$48.70M
YoY Change 6.01% -299.38% 83.08%
INVESTING ACTIVITIES
Capital Expenditures -$800.0K -$100.0K -$400.0K
YoY Change 33.33% -75.0% -50.0%
Acquisitions
YoY Change
Other Investing Activities -$89.30M $49.50M $7.300M
YoY Change -328.39% 578.08% -58.29%
Cash From Investing Activities -$90.10M $49.50M $6.900M
YoY Change -334.03% 617.39% -58.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 200.0K 1.500M 700.0K
YoY Change 114.29% 0.0%
NET CHANGE
Cash From Operating Activities -24.70M 97.10M -48.70M
Cash From Investing Activities -90.10M 49.50M 6.900M
Cash From Financing Activities 200.0K 1.500M 700.0K
Net Change In Cash -114.6M 148.1M -41.10M
YoY Change -853.95% -460.34% 346.74%
FREE CASH FLOW
Cash From Operating Activities -$24.70M $97.10M -$48.70M
Capital Expenditures -$800.0K -$100.0K -$400.0K
Free Cash Flow -$23.90M $97.20M -$48.30M
YoY Change 5.29% -301.24% 87.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001501989
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 ctmx Net Operating Loss Carryback Period
NetOperatingLossCarrybackPeriod
P5Y
CY2019Q1 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201802Member
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y4M2D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y10M6D
CY2020Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2019Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37587
dei Entity Registrant Name
EntityRegistrantName
CytomX Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3521219
dei Entity Address Address Line1
EntityAddressAddressLine1
151 Oyster Point Blvd
dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value per share
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
51894000
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
515-3185 
dei Trading Symbol
TradingSymbol
CTMX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46192226
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
248494000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
292305000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
130883000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
465000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5192000
CY2019Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
155000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-14124000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
122571000
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
665000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5454000
CY2019Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
136000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-28960000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
101501000
us-gaap Profit Loss
ProfitLoss
-3474000
us-gaap Profit Loss
ProfitLoss
-43085000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
72000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
73000
ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
1187000
ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
1247000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
314000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1407000
us-gaap Share Based Compensation
ShareBasedCompensation
7526000
us-gaap Share Based Compensation
ShareBasedCompensation
10646000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1602000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9907000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12782000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-636000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
579000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3000
ctmx Increase Decrease In Accrued Liabilities Income Tax Payable And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent
-9887000
ctmx Increase Decrease In Accrued Liabilities Income Tax Payable And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent
-20104000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
64014000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-28470000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
47364000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-87682000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1086000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2166000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
44707000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
101643000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
97687000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
92143000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11666000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3705000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
102963000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-98185000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
189342000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
618000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
412000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
28054000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the Business</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CytomX Therapeutics, Inc. (the “Company”) is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapeutics. The Company is pioneering a novel class of investigational antibody therapeutics, based on its Probody® therapeutic technology platform, for the treatment of cancer. The Probody therapeutic approach is designed to more specifically target antibody therapeutics to the tumor microenvironment and minimize drug activity in healthy tissue and in circulation. The Company is located in South San Francisco, California and was incorporated in the state of Delaware in September 2010.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p>
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
291388000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
188425000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
149392000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
247577000
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2019Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
292305000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
189342000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
150309000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
248494000
CY2020Q2 ctmx Cash Cash Equivalents And Short Term Investments Amortized Cost Basis
CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis
296071000
CY2020Q2 ctmx Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax
69000
CY2020Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
296140000
CY2019Q4 ctmx Cash Cash Equivalents And Short Term Investments Amortized Cost Basis
CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis
279284000
CY2019Q4 ctmx Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax
110000
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
279394000
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
0
CY2020Q2 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
11831000
CY2019Q4 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
19006000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6721000
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1202000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2998000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2810000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21147000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30051000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.26
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3317144
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.25
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
594667
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.61
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1026095
CY2019Q2 us-gaap Revenues
Revenues
9013000
us-gaap Revenues
Revenues
66201000
us-gaap Revenues
Revenues
38498000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
230239000
ctmx Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
120000000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
55986000
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
294253000
ctmx Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
120000000.0
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
56000000.0
ctmx Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
120000000.0
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
294300000
CY2019Q2 ctmx Royalty Obligations Future Minimum Payments Due
RoyaltyObligationsFutureMinimumPaymentsDue
200000
ctmx License Termination Period
LicenseTerminationPeriod
P60D
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9936168
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13.34
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11632550
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.08
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6277291
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.36
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3513000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5454000
CY2019Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1300000
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1300000
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1239000
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1205000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25382000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2998000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2810000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23323000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
24871000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
26321000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
27681000
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2512000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5129000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5273000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5420000
CY2020Q2 ctmx Lessee Operating Lease Liability Payments Due Year Four And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter
15689000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
34023000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7702000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
26321000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-13900000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6000
CY2020Q1 ctmx Percentage Of Taxable Income From Net Operating Losses For Suspension Of Annual Deduction Limitation
PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation
0.80

Files In Submission

Name View Source Status
0001564590-20-037722-index-headers.html Edgar Link pending
0001564590-20-037722-index.html Edgar Link pending
0001564590-20-037722.txt Edgar Link pending
0001564590-20-037722-xbrl.zip Edgar Link pending
ctmx-10q_20200630.htm Edgar Link pending
ctmx-10q_20200630_htm.xml Edgar Link completed
ctmx-20200630.xsd Edgar Link pending
ctmx-20200630_cal.xml Edgar Link unprocessable
ctmx-20200630_def.xml Edgar Link unprocessable
ctmx-20200630_lab.xml Edgar Link unprocessable
ctmx-20200630_pre.xml Edgar Link unprocessable
ctmx-ex311_16.htm Edgar Link pending
ctmx-ex312_15.htm Edgar Link pending
ctmx-ex321_14.htm Edgar Link pending
ctmx-ex322_13.htm Edgar Link pending
ctmx-ex44_216.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R47.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending